This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

16 May 2011

Allos Inks $360M Pact for Cancer Drug Folotyn

Allos Therapeutics Inc. said it has reached a deal with a U.K. company to co-develop Allos’ cancer drug Folotyn.

Westminster-based Allos Therapeutics announced an ex-North American licensing pact for Folotyn last week which will deliver $50 million upfront and up to $310.5 million in milestones. In exchange Mundipharma International gets marketing rights outside of the U.S. and Canada.


Related News